Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024
September 17, 2024 11:45 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – September 17, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data and analyses of daridorexant, Idorsia’s dual orexin receptor antagonist for the treatment of adults...
New data on aprocitentan to be presented at the AHA Hypertension Scientific Sessions 2024
September 05, 2024 11:45 ET
|
Idorsia Pharmaceuticals Ltd
Two abstracts win the prestigious AHA 2024 Paul Dudley White International Scholar Award Allschwil, Switzerland – September 5, 2024Idorsia Ltd (SIX: IDIA) today announced that new data on...
Amended terms of Idorsia’s 2024 convertible bonds become effective
September 02, 2024 11:45 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – September 2, 2024 Idorsia Ltd (SIX: IDIA) today announced that following the expiry of the appeal period – during which no appeal...
Idorsia announces financial results for the first half 2024
July 25, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 25, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2024. Business highlights ...
Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension
July 01, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Idorsia receives approval from the European Commission (EC) for JERAYGO™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension.JERAYGO...
Higher cantonal composition authority issues written court decision in respect to the amendments to the terms of the 2024 convertible bonds
June 28, 2024 11:45 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – June 28, 2024 Idorsia Ltd (SIX: IDIA) today announced that it has received the written decision from the higher cantonal composition authority (obere kantonale...
Higher cantonal composition authority approved the amendments to the terms of the 2024 convertible bonds
June 25, 2024 11:45 ET
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – June 25, 2024 Idorsia Ltd (SIX: IDIA) today announced that the hearing by the higher cantonal composition authority (obere...
Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’ category
June 21, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Idorsia’s dual orexin receptor antagonist, a drug working by a new mechanism of action for the treatment of chronic insomnia, has been awarded the prestigious Prix Galien Suisse 2024 innovation prize...
Idorsia holds its Annual General Meeting of Shareholders
June 13, 2024 05:00 ET
|
Idorsia Pharmaceuticals Ltd
All Board proposals approved by the shareholders Allschwil, Switzerland – June 13, 2024At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders...
New data with daridorexant to be presented at SLEEP 2024
June 03, 2024 01:00 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – June 3, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data with daridorexant, Idorsia’s dual orexin receptor antagonist for the treatment of adults with insomnia,...